Your browser doesn't support javascript.
loading
Unraveling the Antioxidant Capacity of Spatholobi caulis in Nonalcoholic Fatty Liver Disease: A Multiscale Network Approach Integrated with Experimental Validation.
Bae, Su-Jin; Lee, Won-Yung; Bak, Seon-Been; Kim, Young-Eun; Kim, Min-Jin; Kim, Young-Woo.
Afiliação
  • Bae SJ; School of Korean Medicine, Dongguk University, Gyeonju 38066, Republic of Korea.
  • Lee WY; School of Korean Medicine, Dongguk University, Gyeonju 38066, Republic of Korea.
  • Bak SB; School of Korean Medicine, Dongguk University, Gyeonju 38066, Republic of Korea.
  • Kim YE; School of Korean Medicine, Dongguk University, Gyeonju 38066, Republic of Korea.
  • Kim MJ; School of Korean Medicine, Dongguk University, Gyeonju 38066, Republic of Korea.
  • Kim YW; School of Korean Medicine, Dongguk University, Gyeonju 38066, Republic of Korea.
Antioxidants (Basel) ; 12(5)2023 May 13.
Article em En | MEDLINE | ID: mdl-37237962
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is a global health problem that is closely associated with obesity and metabolic syndrome. Spatholobi caulis (SC) is a herbal medicine with potential hepatoprotective effects; however, its active compounds and underlying mechanisms have not been fully explored. In this study, we combined a multiscale network-level approach with experimental validation to investigate SC's antioxidant properties and their impact on NAFLD. Data collection and network construction were performed, and active compounds and key mechanisms were identified through multi-scale network analysis. Validation was conducted using in vitro steatotic hepatocyte models and in vivo high-fat diet-induced NAFLD models. Our findings revealed that SC treatment improved NAFLD by modulating multiple proteins and signaling pathways, including AMPK signaling pathways. Subsequent experiments showed that SC treatment reduced lipid accumulation and oxidative stress. We also validated SC's effects on AMPK and its crosstalk pathways, emphasizing their role in hepatoprotection. We predicted procyanidin B2 to be an active compound of SC and validated it using a lipogenesis in vitro model. Histological and biochemical analyses confirmed that SC ameliorated liver steatosis and inflammation in mice. This study presents SC's potential use in NAFLD treatment and introduces a novel approach for identifying and validating active compounds in herbal medicine.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article